171 related articles for article (PubMed ID: 27154156)
1. Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?
Lee A; Wong AT; Schwartz D; Weiner JP; Osborn VW; Schreiber D
Ann Thorac Surg; 2016 Aug; 102(2):433-8. PubMed ID: 27154156
[TBL] [Abstract][Full Text] [Related]
2. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
3. Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients.
Azab B; Amundson JR; Picado O; Ripat C; Macedo FI; Franceschi D; Livingstone AS; Yakoub D
Ann Surg Oncol; 2019 Mar; 26(3):861-868. PubMed ID: 30311162
[TBL] [Abstract][Full Text] [Related]
4. Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer.
Haisley KR; Laird AE; Nabavizadeh N; Gatter KM; Holland JM; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
JAMA Surg; 2016 Nov; 151(11):e162743. PubMed ID: 27627765
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes.
Buckstein M; Rhome R; Ru M; Moshier E
Dis Esophagus; 2018 May; 31(5):. PubMed ID: 29309563
[TBL] [Abstract][Full Text] [Related]
7. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
8. Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer.
Shaikh T; Thomay A; Ruth K; Cohen SJ; Meyer JE
J Surg Oncol; 2015 Nov; 112(6):629-33. PubMed ID: 26430952
[TBL] [Abstract][Full Text] [Related]
9. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
10. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
[TBL] [Abstract][Full Text] [Related]
12. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
13. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
14. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
15. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
16. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
[TBL] [Abstract][Full Text] [Related]
17. Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.
Tapias LF; Mathisen DJ; Wright CD; Wain JC; Gaissert HA; Muniappan A; Lanuti M; Donahue DM; Morse CR
Ann Thorac Surg; 2016 Mar; 101(3):1097-103. PubMed ID: 26652140
[TBL] [Abstract][Full Text] [Related]
18. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
20. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
